Therapeutic Product Immunogenicity Community

Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs) - The AAPS Journal SpringerLink remove preview Considerations in the Immunogenicity Assessment Strategy for Oligonucleotide Therapeutics (ONTs) - The AAPS Journal Oligonucleotide therapeutics (ONTs) are a diverse group of short synthetic nucleic acid-based molecules that exploit innovative intracellular molecular strategies to create novel treatments for a variety of medical conditions. ONT molecules (~7-15 kDa) reside between traditional large and small molecules, and there has been debate regarding their immunogenicity risk. View this on SpringerLink >

To view the full article through your AAPS membership:

Go to https://www.aaps.org/education-and-research/journals/the-aaps-journal 

Enter your AAPS credentials

Click "Member Access to Journals"

Click on the The AAPS Journal cover.

Copy and paste the url into the "Search" box, and click search

The full article should appear.

------------------------------
Ho-Leung Fung Ph.D., FAAPS
Editor-in-Chief
University at Buffalo
Sarasota FL
[email protected]

Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------